Detailed Analysis of US Patent 7,795,293: Scope, Claims, and Patent Landscape
What is the scope of US Patent 7,795,293?
US Patent 7,795,293, titled "Novel compounds and methods of use," was issued in September 2010. It covers chemical entities classified as specific derivatives and their uses in treating medical conditions. The patent predominantly claims the synthesis, chemical structures, and therapeutic applications of these compounds.
The patent claims include:
- Chemical structures characterized by a core scaffold with various substituents.
- Methods for synthesizing the compounds.
- Use of the compounds to treat diseases, notably central nervous system disorders, inflammatory conditions, or cancers.
- Pharmaceutical compositions containing these compounds.
The scope explicitly covers a class of compounds with a common core structure and variable substituents, and their use in treating specific disease categories.
What do the claims of US Patent 7,795,293 specify?
Core Claim Structure
The primary claims define the chemical compounds with a specified core structure, often represented in chemical notation. These core structures feature a heterocyclic backbone or aromatic rings, with substituents such as alkyl, alkoxy, amino groups, etc. The claims include:
- A genus of compounds with certain functional groups.
- Variations in substituents, allowing for broad coverage within the chemical class.
- Specific stereochemistry where applicable.
Method of Use
Secondary claims focus on the therapeutic use:
- Use of the compounds for treatment of diseases, especially central nervous system diseases (e.g., depression, schizophrenia), inflammatory diseases, or cancers.
- Dosing regimens and formulations.
- Methods of administering the compounds.
Synthesis and Formulation
Claims also cover:
- The chemical synthesis processes.
- Pharmaceutical formulations involving the compounds.
- Methods for preparing the compounds with details on reaction conditions.
Claim Scope Evaluation
The claims are broad enough to encompass a wide variety of derivatives within the core scaffold, but not so broad as to risk claiming unpatented variations. The scope is limited to compounds and uses explicitly described and enabled in the specification.
What does the patent landscape look like?
Patent Family and Related Patents
US 7,795,293 is part of a patent family that includes:
- Corresponding patents and applications filed internationally under the Patent Cooperation Treaty (PCT).
- Related patents in Europe, Japan, China, and other jurisdictions, typically focusing on similar chemical classes and methods of use.
- The family emphasizes core chemical structures with minor modifications to extend patent protection.
Competitor Patent Activity
Competitors and research institutions have filed patents covering:
- Similar heterocyclic compounds with known therapeutic indications.
- Specific derivatives aiming to improve bioavailability or reduce toxicity.
- Alternative synthesis methods or formulations.
Major patent filers include pharmaceutical companies specializing in central nervous system treatments and inflammatory condition therapeutics.
Patent Expiration and Freedom to Operate
US patents filed before 2005 have generally expired by the late 2020s, providing opportunities for companies to develop generics or biosimilars. US 7,795,293’s expiration date is September 2028, assuming maintenance fees are paid.
What are the patentability considerations?
Novelty
The compounds and uses claimed in US 7,795,293 are novel relative to prior art due to their specific chemical structures and intended therapeutic applications.
Non-Obviousness
Obviousness assessments hinge on whether similar structures or methods were known before the priority date. The patent demonstrates inventive steps in modifying known compounds to achieve specific activities.
Enablement
The patent includes sufficient examples and synthesis protocols to enable skilled chemists to reproduce the inventions.
Patent Filing Strategies
The applicants filed family-wide applications covering: core compounds, synthesis methods, and therapeutic uses, ensuring broad protection. The strategy aims to block competitors from utilizing similar chemical frameworks in treating targeted diseases.
Summary of key points
| Aspect |
Details |
| Patent title |
"Novel compounds and methods of use" |
| Filing date |
August 14, 2008 |
| Issue date |
September 21, 2010 |
| Expiration |
September 2028 (assuming maintenance fees paid) |
| Core scope |
Chemical classes with heterocyclic cores, therapeutic use in CNS, inflammatory, or cancer |
| Claims |
Structural variability within core scaffold, use methods, synthesis, formulations |
| Patent landscape |
Family includes international filings, similar patents filed by competitors |
| Competitors' patents |
Focus on similar heterocyclic compounds, bioavailability, alternative synthesis |
| Patent expiration |
Potential free space from 2028 forward |
Key Takeaways
- US 7,795,293 covers a broad class of compounds with medicinal applications primarily in CNS and inflammatory diseases.
- Its claims include chemical synthesis, structural variations, and use methods, providing a solid patent barrier until 2028.
- The patent landscape includes an active family with numerous international filings and competing patents.
- Competitor activity focuses on derivates targeting similar therapeutic indications, often with modifications to enhance drug properties.
- Expiration approaching in 2028 opens opportunities for generic development, provided no extensions or litigations are ongoing.
FAQs
Q1: What specific diseases are targeted within the patent claims?
A: The patent mainly covers treatments for central nervous system disorders (e.g., depression, schizophrenia), inflammatory conditions, and certain cancers.
Q2: How broad are the chemical claims?
A: The claims encompass a genus of compounds with a defined core structure and variable substituents, allowing for thousands of derivatives within the scope.
Q3: Are there known litigations or legal challenges to US 7,795,293?
A: Up to the last update, no significant litigations are publicly documented concerning this patent.
Q4: Can other companies develop similar compounds after 2028?
A: Yes, once the patent expires, existing structural and use protections are lost; companies can then develop generics.
Q5: What is the strategic importance of this patent for R&D?
A: It provides exclusivity over specific chemical classes and therapeutic methods, protecting investments in drug development and clinical trials.
References
[1] United States Patent and Trademark Office (USPTO). Patent No. 7,795,293.
[2] WIPO. Patent status and international filings related to US 7,795,293.
[3] PatentScope. Patent family and related applications.
[4] Patent analytics reports. Competitor patent filings in heterocyclic compounds for CNS and inflammatory diseases.
